The Interactions Between Alzheimer’s Disease and Major Depression: Role of Ca2+ Channel Blockers and Ca2+/cAMP Signalling

Author(s): Leandro Bueno Bergantin*

Journal Name: Current Drug Research Reviews
(Formerly Current Drug Abuse Reviews)

Volume 12 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The interactions between Alzheimer’s Disease (AD) and major depression can be translated into clinical data showing that depressive patients have had an enhanced risk for developing AD (later in life). The cellular mechanisms involved in these interactions remain under intensive debate in the literature. In addition, the role of a Ca2+ homeostasis dysregulation in the pathogenesis of neurodegenerative diseases, like AD, and major depression has been under intensive discussion.

Objective: Thus, revealing the interplay between AD and major depression may provide novel insights into the pathogenesis of these diseases.

Methods: Publications involving Ca2+ signalling pathways, AD, and major depression (alone or combined) were collected by searching multiple databases to find the maximum number of relevant citations (using a search strategy with high sensitivity for studies of etiology).

Results: Ca2+ Channel Blockers (CCBs), classically prescribed for hypertensive patients, have been demonstrating neuroprotective effects, such as decreasing the incidence of AD in hypertensive patients, including alleviating major depression symptoms. A mechanism under debate is focused on the restoration of the Ca2+ homeostasis. Indeed, previous studies of our own have correlated Ca2+ and cAMP signalling pathways (Ca2+/cAMP signalling) in controlling both the neurotransmitter release and neuronal death. These studies also observed that CCBs can affect Ca2+/cAMP signalling.

Conclusion: This review discussed the plausible role of Ca2+/cAMP signalling in the neuroprotective effects of CCBs, including the participation of Ca2+/cAMP signalling in the interactions between major depression and AD. Considering both AD and major depression have become highly prevalent medical problems in the world, the comprehension of the interactions between these diseases could improve drug development.

Keywords: Alzheimer´s disease, major depression, Ca2+/cAMP signaling, neuroprotective, neurotransmitter, proteolysis.

[1]
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63(5): 530-8.
[http://dx.doi.org/10.1001/archpsyc.63.5.530] [PMID: 16651510]
[2]
Bergantin LB, Caricati-Neto A. Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)/cAMP intracellular signalling interaction. Eur J Pharmacol 2016; 788: 255-60.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.034] [PMID: 27349146]
[3]
Bergantin LB, Souza CF, Ferreira RM, Smaili SS, Jurkiewicz NH, Caricati-Neto A, et al. Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway. Cell Calcium 2013 Sep; 54(3): 202-12.
[http://dx.doi.org/10.1016/j.ceca.2013.06.004] [PMID: 23849429]
[4]
Bergantin LB. Neurodegenerative Diseases: Where to go from now? Thought provoking through Ca2+/cAMP signaling interaction. Brain Disord Ther 2017; 6(04)
[http://dx.doi.org/10.4172/2168-975X.1000e125]
[5]
Bergantin LB. Neurological disorders: Is there a horizon? Emerging ideas from the interaction between Ca2+ and camp signaling pathways. J Neurol Disord 2017; 5(6)
[http://dx.doi.org/10.4172/2329-6895.1000e124]
[6]
Caricati-Neto A, García AG, Bergantin LB. Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect 2015; 3(5): 181.
[http://dx.doi.org/10.1002/prp2.181] [PMID: 26516591]
[7]
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 2008; 31(9): 454-63.
[http://dx.doi.org/10.1016/j.tins.2008.06.005] [PMID: 18675468]
[8]
Caricati-Neto A, Bergantin LB. Pharmacological modulation of neural Ca2+/camp signaling interaction as therapeutic goal for treatment of Alzheimer’s disease. J Syst Integr Neurosci 2017; 3.
[http://dx.doi.org/10.15761/JSIN.1000185]
[9]
Caricati-Neto A, Bergantin LB. The passion of a scientific discovery: the “calcium paradox” due to Ca2+/camp interaction. J Syst Integr Neurosci 2017; 3.
[http://dx.doi.org/10.15761/JSIN.1000186]
[10]
Caricati-Neto A, Bueno Bergantin L. From a “eureka insight” to a novel potential therapeutic target to treat Parkinson’s disease: The Ca2+/camp signalling interaction. J Syst Integr Neurosci 2018; 4(1)
[http://dx.doi.org/10.15761/JSIN.1000187]
[11]
Bergantin LB, Caricati-Neto A. Insight from “Calcium Paradox” due to Ca2+/cAMP Interaction: Novel Pharmacological Strategies for the Treatment of Depression. Int Arch Clin Pharmacol 2016; 2: 7.
[http://dx.doi.org/10.23937/2572-3987.1510007]
[12]
Wu CL, Wen SH. A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine 2016; 95(32)
[http://dx.doi.org/10.1097/MD.0000000000004593] [PMID: 27512890]
[13]
Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in europe (syst-eur) trial investigators. Lancet 1997; 350(9080): 757-64.
[http://dx.doi.org/10.1016/S0140-6736(97)05381-6] [PMID: 9297994]
[14]
Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in europe (syst-eur) trial. Lancet 1998 Oct 24; 352(9137): 1347-51.
[http://dx.doi.org/10.1016/S0140-6736(98)03086-4] [PMID: 9802273]
[15]
Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001; 153(1): 72-8.
[http://dx.doi.org/10.1093/aje/153.1.72] [PMID: 11159149]
[16]
Bergantin LB, Caricati-Neto A. Novel concepts for clinical pharmacology from “calcium paradox” due to neuronal interaction between signalling pathways mediated by ca2+ and camp: from 1975 to 2017. Int Arch Clin Pharmacol 2017; 3: 13.
[17]
Bergantin LB, Caricati-Neto A. Emerging concepts for neuroscience field from ca2+/camp signalling interaction. J Neurol Exp Neurosci 2017; 3(1): 29-32.
[http://dx.doi.org/10.17756/jnen.2017-024]
[18]
Bergantin LB. Advances for the pharmacotherapy of depression - Presenting the rising star: Ca2+/camp signaling interaction. J Syst Integr Neurosci 2017; 3.
[http://dx.doi.org/10.15761/JSIN.1000161]
[19]
Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer’s disease: A population-based case-control study. Neurolog 1991; 41(9): 1393-7.
[http://dx.doi.org/10.1212/WNL.41.9.1393] [PMID: 1891088]
[20]
Speck CE, Kukull WA, Brenner DE, et al. History of depression as a risk factor for Alzheimer’s disease. Epidemiology 1995; 6(4): 366-9.
[http://dx.doi.org/10.1097/00001648-199507000-00006] [PMID: 7548342]
[21]
Tsolaki M, Fountoulakis K, Chantzi E, Kazis A. Risk factors for clinically diagnosed Alzheimer’s disease: A case-control study of a Greek population. Int Psychogeriatr 1997; 9(3): 327-41.
[http://dx.doi.org/10.1017/S104161029700447X] [PMID: 9513031]
[22]
Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003; 60(5): 753-9.
[http://dx.doi.org/10.1001/archneur.60.5.753] [PMID: 12756140]
[23]
Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34(2): 335-7.
[http://dx.doi.org/10.1161/01.STR.0000054050.51530.76] [PMID: 12574528]
[24]
Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer’s disease: Review and hypothesis. J Gerontol A Biol. Med Sci 2004; 59: M178-83.
[25]
Parissis JT, Adamopoulos S, Rigas A, et al. Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004; 94(10): 1326-8.
[http://dx.doi.org/10.1016/j.amjcard.2004.07.127] [PMID: 15541260]
[26]
Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999; 4(4): 328-32.
[http://dx.doi.org/10.1038/sj.mp.4000572] [PMID: 10483048]
[27]
Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004; 29(9): 1119-28.
[http://dx.doi.org/10.1016/j.psyneuen.2004.01.002] [PMID: 15219635]
[28]
St George-Hyslop PH, Petit A. Molecular biology and genetics of Alzheimer’s disease. C R Biol 2005; 328(2): 119-30.
[http://dx.doi.org/10.1016/j.crvi.2004.10.013] [PMID: 15770998]
[29]
Duman RS. Depression: A case of neuronal life and death? Biol Psychiatry 2004; 56(3): 140-5.
[http://dx.doi.org/10.1016/j.biopsych.2004.02.033] [PMID: 15271581]
[30]
Douglas WW, Rubin RP. The role of calcium in the secretory response of the adrenal medulla to acetylcholine. J Physiol 1961; 159: 40-57.
[http://dx.doi.org/10.1113/jphysiol.1961.sp006791 PMID: 13887557]
[31]
Baker PF, Knight DE. Calcium-dependent exocytosis in bovine adrenal medullary cells with leaky plasma membranes. Nature 1978; 276(5688): 620-2.
[http://dx.doi.org/10.1038/276620a0] [PMID: 723944]
[32]
Kreye VA, Lüth JB. Proceedings: Verapamil-induced phasic contractions of the isolated rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 1975; 287.
[PMID: 1143442]
[33]
French AM, Scott NC. A comparison of the effects of nifedipine and verapamil on rat vas deferens. Br J Pharmacol 1981; 73(2): 321-3.
[http://dx.doi.org/10.1111/j.1476-5381.1981.tb10424.x PMID: 7236986]
[34]
Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, Fukuda H. Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol 1987; 140(1): 75-83.
[http://dx.doi.org/10.1016/0014-2999(87)90636-4] [PMID: 3113986]
[35]
Sommer N, Löschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995; 1(3): 244-8.
[http://dx.doi.org/10.1038/nm0395-244] [PMID: 7585041]
[36]
Xiao L, O’Callaghan JP, O’Donnell JM. Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test. J Pharmacol Exp Ther 2011; 338(2): 641-7.
[http://dx.doi.org/10.1124/jpet.111.179358] [PMID: 21566211]
[37]
Tully PJ, Peters R, Pérès K, Anstey KJ, Tzourio C. Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study. Int Psychogeriatr 2018; 30(9): 1345-54.
[http://dx.doi.org/10.1017/S1041610217002903] [PMID: 29559030]
[38]
Bergantin LB. Debating the “bidirectional link” between diabetes and depression through the Ca2+/cAMP signalling: Off-label effects of Ca2+ channel blockers. Pharmacol Res 2019; 141: 298-302.
[http://dx.doi.org/10.1016/j.phrs.2019.01.008] [PMID: 30639385]
[39]
Bergantin LB. Hypertension, diabetes and neurodegenerative diseases: is there a clinical link through the ca2+/camp signalling interaction? Curr Hypertens Rev 2019; 15(1): 32-9.
[http://dx.doi.org/10.2174/1573402114666180817113242] [PMID: 30117399]
[40]
Bergantin L, Caricati-Neto A. The “calcium paradox” and its impact on neurological and psychiatric diseases. 2nd ed. Cambridge Scholars Publishing 2018.
[41]
Kennelly S, Collins O. Walking the cognitive “Minefield” between high and low blood pressure. J Alzheimers Dis 2012; 32(3): 609-21.
[http://dx.doi.org/10.3233/JAD-2012-120748] [PMID: 22810098]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 2
Year: 2020
Page: [97 - 102]
Pages: 6
DOI: 10.2174/2589977512666200217093356
Price: $65

Article Metrics

PDF: 27
HTML: 1